MAR 2018
The global acute myeloid leukemia market is expected to register a CAGR of 14% during the forecast period of 2018-2023. Due to the higher awareness of the condition and the drugs that treat it, and continued acceptance toward existing therapeutics, North America dominates the market studied.
Acute Myeloid Leukemia (AML) is very common in adults and accounts for 80% of cases. In the United States, the incidence of AML ranges from three to five cases for a population of 100,000. According to a cancer statistics in 2015, there are 20,830 new cases that are diagnosed and 10,000 have died from this disease. Increasing expenditure on healthcare. According to data from the centers on Medicare and Medicaid Services, the United States spent USD 3.2 trillion on healthcare, in 2015.
Additionally, increasing investment in R&D and advancement in pharmacology and molecular biology, to promote drug development, are also driving the global acute myeloid leukemia therapeutics market.
Chemotherapy treats various types of cancer. However, it also causes varied side-effects in different patients at different locations, which mainly depend on the type of cancer, location of the cancer, drugs and their dosage, and general health of the individual. The common side-effects of chemotherapy include - headache, muscle pain, stomach pain, and pain from nerve damage, which refers to burning and numbness.
Additionally, stringent regulatory guidelines of the government in various countries are restraining the global acute myeloid leukemia therapeutics market.
The global acute myeloid leukemia therapeutics market has been segmented by chemotherapy and geography. The chemotherapy segment includes CALGB 8811 regimen, hyper – CVAD regimen, Oncaspar, linker regimen, nucleoside inhibitors, and others. Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
North America dominates the acute myeloid leukemia therapeutics market, due to the rising incidence of acute myeloid leukemia therapeutics, rise in the healthcare expenditure in the region, high investments on the development of pipeline drugs, and awareness among the people for the treatment of the acute myeloid leukemia therapeutics. Asia-Pacific is expected to be the fastest growing region over the forecast period.
Major Players: Genmab A/S, GlaxoSmithKline, Bristol Myer Squibb, Novartis AG, Roche, Celegene Corporation, and Eisai Co. Ltd, amongst others.
